SOURCE: Nanosphere

May 16, 2013 08:25 ET

New Validation and Clinical Outcome Data From Several Studies on Nanosphere's Gram-Positive and Gram-Negative Blood Culture Tests to Be Presented at ASM 2013

NORTHBROOK, IL--(Marketwired - May 16, 2013) - Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that new validation and outcome data for select Verigene® clinical microbiology tests will be presented at the 113th General Meeting of the American Society for Microbiology (ASM) being held in Denver, CO from May 18 to May 21.

At the ASM meeting, eleven posters from various U.S. and international medical facilities will present validation data for the Verigene Gram-Positive Blood Culture (BC-GP) (510(k) cleared; CE Mark), Gram-Negative Blood Culture (BC-GN) (RUO; CE Mark), and Clostridium difficile (CDF) Nucleic Acid (510(k) cleared; CE Mark) Tests. These posters will highlight the accuracy and clinical utility for each of these tests, underlining the important role of rapid, comprehensive diagnostics in potentially facilitating better patient treatment decisions. Clinical outcome data from one study in particular will describe the time savings to optimal antibiotic treatment and the positive clinical impact of the Verigene System within a healthcare institution.

"Nanosphere will have a highly visible presence at this year's ASM meeting and we look forward to providing significant data that further demonstrates the compelling value of Nanosphere's Verigene System as an easy-to-use, molecular diagnostic test platform that provides physicians with timely and clinically actionable information," said Michael McGarrity, Nanosphere's president and chief executive officer. "We believe rapid results directly affect patient outcomes and reduce medical costs as they enable earlier detection of life-threatening diseases and allow physicians to optimize antibiotic therapy."

Select Nanosphere Abstracts at ASM (publicly available in the ASM 2013 Final Program) (

Poster LB-01: "Identification of Gram-Positive Bacteria from Episodes of Pediatric Bacteremia using the BacT/ALERT Blood Culture Bottles and the Verigene BC-GP Assay," C. Haag et al.; Dallas Children's Medical Center, TX. [Sunday, May 19th, 10:45 am - 12:30 pm]

Poster 111: "Evaluation of Three Rapid Diagnostics Assays to Directly Identify Organisms from Positive Blood Cultures," R. M. Martinez et al.; University of Washington, WA. [Sunday, May 19th, 10:45 am - 12:30 pm]

Poster 134: "Evaluation of Automated Rapid Diagnostic Test for Direct Identification of Gram-Negative Bacteria from Positive Blood Cultures," M. Tojo et al.; Disease Control and Prevention Center, Tokyo, Japan. [Sunday, May 19th, 10:45 am - 12:30 pm] 

Poster 1803: "Evaluation of the Nanosphere Verigene BC-GP test for Direct Detection of Gram-Positive Bacteria and Resistance Genes from Positive Blood Cultures in Pediatric Patients," J. Dien Bard et al.; Children's Hospital of Los Angeles, CA. [Tuesday, May 21st, 10:45 am - 12:30 pm]

Poster 1804: "Evaluation of the Comparative Performance of Verigene Gram-Positive Blood Culture Nucleic Acid System to Conventional and Other Nucleic Acid Techniques in a Tertiary-Care Hospital in Kuwait," I. M. A. H. Mokaddas et al.; Ibn Sina Hospital, Kuwait. [Tuesday, May 21st, 10:45 am - 12:30 pm]

Poster 1813: "The Diagnostic Accuracy of Verigene BC-GP for the Detection of Pathogenic Gram-Positive Organisms from Positive Blood Culture in a Veteran Population," C. Hongsermeier et al.; VA Eastern Colorado Healthcare System, CO. [Tuesday, May 21st, 10:45 am - 12:30 pm]

Poster 1814: "Evaluation of the Nanosphere Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP)," R. Podzorski et al.; Waukesha Memorial Hospital, WI. [Tuesday, May 21st, 10:45 am - 12:30 pm]

Poster 1817: "Accurate and Rapid Detection of Gram-Positive Organisms Using the Verigene Gram-positive Blood Culture Test in a Tertiary Pediatric Population," N. N. Turner et al.; Children's Hospital of Philadelphia, PA. [Tuesday, May 21st, 10:45 am - 12:30 pm]

Poster 2273: "Laboratory Verification of the Verigene Nanosphere Clostridium difficile Nucleic Acid Test," S. Tan et al.; The Johns Hopkins Hospital, MD. [Tuesday, May 21st, 1:00 pm - 2:45 pm]

With more than 39,000 members representing 26 disciplines of microbiological specialization, ASM is the single largest life science membership organization in the world. During the annual General Meeting, microbiologists present their work and gain valuable insight across a variety of scientific disciplines.

About Nanosphere, Inc.

Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for multiplexed infectious disease, genetic, and ultra-sensitive protein testing. This easy-to-use platform offers laboratories a convenient, simple, and cost-effective solution for highly sensitive nucleic acid and protein testing. Nanosphere is based in Northbrook, IL.

For additional information regarding Nanosphere's infectious disease products, please contact Nanosphere at or visit

Contact Information

  • Contact:
    Nanosphere, Inc.
    Roger Moody
    Chief Financial Officer

    Nanosphere, Inc.
    Lindsey Saxon
    Director of Communications